Supported by phase 3 SYMPHONY and ENCORE trial data, AXS-12 significantly reduced weekly cataplexy attacks and improved daytime sleepiness and cognition.

In response to a rising multistate outbreak of Cyclospora infections, the Centers for Disease Control and Prevention (CDC) has issued a health advisory for clinicians. This summary highlights the ...

At 12 months, adults with insulin-treated diabetes had significant improvements in HbA1c and hospitalizations.

Targeting effective control of rheumatoid arthritis disease activity is crucial component of treatment strategy.